Skip to main content

Table 1 Correlation between TATI serum levels and clinicopathological characteristics

From: Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients

Categories calculated via ROC-curve:

< 15.59

> 15.59

total

P-value

missing

Ranges (s-TATI μg/l)

4.346-15.587

15.588-168.570

   

n(%)

192(59.3)

132(40.7)

324(100)

  

Age

     

< 75

129(69.7)

50(40.7)

179(58.1)

  

≥75

56(30.3)

73(59.3)

129(41.9)

< 0.001**

16(4.9)

Gender

     

Female

90(46.9)

71(53.8)

161(49.7)

  

Male

102(53.1)

61(46.2)

163(50.3)

0.289

0(0.0)

Disease stage

     

I

26(13.7)

18(13.8)

44(13.8)

  

II

84(44.2)

50(38.5)

134(41.9)

  

III

58(30.5)

37(28.5)

95(29.7)

  

IV

22(11.6)

25(19.2)

47(14.7)

0.284

4(1.2)

Differentiation grade

     

High-moderate

155(80.7)

95(74.2)

250(78.1)

  

Poor

37(19.3)

33(25.8)

70(21.9)

0.168

4(1.2)

Vascular invasion

     

No invasion

164(88.6)

106(86.2)

270(87.7)

  

Invasion

21(11.4)

17(13.8)

38(12.3)

0.519

16(4.9)

Mucinous or non-mucinous

     

Non mucinous tumour

161(87.0)

106(86.2)

267(86.7)

  

Mucinous tumour

24(13.0)

17(13.8)

41(13.3)

0.830

16(4.9)

Colon or rectal cancer

     

Colon cancer

115(59.6)

102(77.9)

217(67.0)

  

Rectal cancer

78(40.4)

29(22.1)

107(33.0)

0.001

0(0)

Colon left or right ex ca recti

     

Right colon

58(50.4)

64(63.4)

122(56.2)

  

Left colon

57(49.6)

37(36.6)

94(43.5)

0.056

1(0.5)

CEA serum

     

< 2,67 μg/L

101(52.6)

57(43.2)

158(48.8)

  

≥ 2,67 μg/L

91(47.4)

75(56.8)

166(51.2)

0.095

0(0)

Preop radiation therapy

     

Received

129(66.8)

110(84.0)

239(73.8)

  

Not received

64(33.2)

21(16.0)

85(26.2)

0.001

0(0)

TATI expression in tissue

     

< 50%

145(81.0)

87(73.7)

232(78.1)

  

≥ 50%

34(19.0)

31(26.3)

65(21.9)

0.138

27(8.3)